CAS 320367-13-3

Lixisenatide

Description:

Lixisenatide is a synthetic peptide that belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, primarily used in the management of type 2 diabetes mellitus. It is characterized by its ability to enhance insulin secretion in response to elevated blood glucose levels, thereby aiding in glycemic control. Lixisenatide is a modified version of the naturally occurring GLP-1, featuring structural alterations that enhance its stability and prolong its action in the body. The substance is administered via subcutaneous injection and has a relatively short half-life compared to other GLP-1 agonists, necessitating once-daily dosing. Its pharmacological effects include promoting satiety, reducing appetite, and slowing gastric emptying, which contribute to weight management in diabetic patients. Additionally, lixisenatide has been studied for its cardiovascular benefits, although its primary role remains in glucose regulation. As with other medications in its class, potential side effects may include gastrointestinal disturbances, such as nausea and vomiting, as well as a risk of pancreatitis.

Formula: C₂₁₅H₃₄₇N₆₁O₆₅S

Lixisenatide

CAS: 320367-13-3

Lixisenatide is an exenatide-related GLP-1 agonist injected once daily for glycemic control in adult diabetes II. In myocardial ischemia-reperfusion injury studies with rats, a cardioprotective activity could be shown. Furthermore, administration of lixisenatide rescued spatial memory and synaptic plasticity from amyloid β-protein-induced impairments. Bachem provides this product solely for uses within the scope of any statute or law providing for an immunity, exemption, or exception to patent infringement (“Exempted Uses”), including but not limited to 35 U.S.C. § 271(e)(1) in the United States, the Bolar type exemption in Europe, and any corresponding exception to patent infringement in any other country. It is the sole responsibility of the purchaser or user of this product, and the purchaser or user of this product agrees to engage only in such Exempted Uses, and to comply with all applicable intellectual property laws and/or regulations. The purchaser of this product agrees to indemnify Bachem against all claims in connection with the performance of the respective commercial agreement (e.g. supply agreement) and possible infringements of intellectual property rights.

Formula: C₂₁₅H₃₄₇N₆₁O₆₅S

Purity: 97.2%

Color and Shape: White Lyophilisate

Molecular weight: 4858.56

Ref: 01-4084106

Lixisenatide

CAS: 320367-13-3

Formula: C₂₁₅H₃₄₇N₆₁O₆₅S

Purity: %

Molecular weight: 4858.4904

Ref: IN-DA00C6LD

Lixisenatide

CAS: 320367-13-3

Lixisenatide: Injectable GLP-1 agonist for T2DM, controls blood sugar.

Formula: C₂₁₅H₃₄₇N₆₁O₆₅S

Color and Shape: Solid

Molecular weight: 4858.49

Ref: TM-TP1340

Lixisenatide

CAS: 320367-13-3

Formula: C₂₁₅H₃₄₇N₆₁O₆₅S

Purity: 95%~99%

Color and Shape: White to Off-white Powder

Molecular weight: 4858.55

Ref: BP-BPPG047

Lixisenatide

CAS: 320367-13-3

Lixisenatide is a peptide hormone that belongs to the class of dipeptidyl peptidase-4 inhibitors. It is used in the treatment of type 2 diabetes, including those with a body mass index (BMI) greater than 27 kg/m2 or who have had type 2 diabetes for more than 10 years. Lixisenatide reduces postprandial blood glucose levels by delaying gastric emptying and increasing glucagon-like peptide-1 (GLP-1) release. Lixisenatide has been shown to be effective in reducing cardiovascular events in people with congestive heart failure. Lixisenatide also has water vapor and cardiac effects that are similar to those of GLP-1 agonists.

Formula: C₂₁₅H₃₄₇N₆₁O₆₅S

Purity: Min. 95%

Molecular weight: 4,858.6 g/mol

Ref: 3D-LIX-3799-PI

Lixisenatide

CAS: 320367-13-3

Custom research peptide; min purity 95%. For different specs please use the Peptide Quote Tool

Formula: C₂₁₅H₃₄₇N₆₁O₆₅S

Molecular weight: 4,858.49 g/mol

Ref: 3D-PP50581